Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Duncan Purtill

Showing results (11-20 of 54) with videos related to

Pageof 6
Sort By:
Blood Cell Therapy|January 30, 2023
Evaluating the Efficacy, Toxicity and Pharmacokinetic Profile of Oral Busulfan in Allogeneic Stem Cell Transplant PatientsRoss Salvaris, Sam Salman, Sean O'Halloran, et al.
Internal Medicine Journal|April 4, 2024
COVID-19 outcomes in haemopoietic stem cell transplant recipients in Western Australia: the value of vaccination and antiviral therapyJacques A J Malherbe, Peter Boan, Duncan Purtill, et al.
Internal Medicine Journal|July 14, 2022
Allogeneic haemopoietic cell transplant services in Australia and New Zealand in the first year of the COVID-19 pandemic: a report from Australia and New Zealand transplant and cellular therapiesJad Othman, Donna Aarons, Ashish Bajel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 28, 2015
Association between Nondominant Unit Total Nucleated Cell Dose and Engraftment in Myeloablative Double-Unit Cord Blood TransplantationDuncan Purtill, Cladd E Stevens, Marissa Lubin, et al.
Cytotherapy|March 25, 2022
An ISCT Stem Cell Engineering Committee Position Statement on Immune Reconstitution: the importance of predictable and modifiable milestones of immune reconstitution to transplant outcomesAlice Bertaina, Allistair Abraham, Carmem Bonfim, et al.
Cytotherapy|December 9, 2021
Curative therapy for hemoglobinopathies: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review comparing outcomes, accessibility and cost of ex vivo stem cell gene therapy versus allogeneic hematopoietic stem cell transplantationAlexis Leonard, Alice Bertaina, Carmem Bonfim, et al.
Blood Advances|July 19, 2023
Early cessation of calcineurin inhibitors is feasible post-haploidentical blood stem cell transplant: the ANZHIT 1 studyJohn Moore, Nada Hamad, David Gottlieb, et al.
Internal Medicine Journal|November 28, 2023
ANZTCT consensus position statement on ruxolitinib in steroid-refractory acute and chronic graft-versus-host diseaseNada Hamad, Ian Bilmon, Lynette Chee, et al.
Nature Medicine|June 6, 2024
Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trialYi-Bin Chen, Mohamad Mohty, Robert Zeiser, et al.
Cytotherapy|December 6, 2023
Engineering the best transplant outcome for high-risk acute myeloid leukemia: the donor, the graft and beyondSafia Belbachir, Allistair Abraham, Akshay Sharma, et al.
Pageof 6

Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
Blood Cell Therapy|January 30, 2023
Evaluating the Efficacy, Toxicity and Pharmacokinetic Profile of Oral Busulfan in Allogeneic Stem Cell Transplant PatientsRoss Salvaris, Sam Salman, Sean O'Halloran, et al.
Internal Medicine Journal|April 4, 2024
COVID-19 outcomes in haemopoietic stem cell transplant recipients in Western Australia: the value of vaccination and antiviral therapyJacques A J Malherbe, Peter Boan, Duncan Purtill, et al.
Internal Medicine Journal|July 14, 2022
Allogeneic haemopoietic cell transplant services in Australia and New Zealand in the first year of the COVID-19 pandemic: a report from Australia and New Zealand transplant and cellular therapiesJad Othman, Donna Aarons, Ashish Bajel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 28, 2015
Association between Nondominant Unit Total Nucleated Cell Dose and Engraftment in Myeloablative Double-Unit Cord Blood TransplantationDuncan Purtill, Cladd E Stevens, Marissa Lubin, et al.
Cytotherapy|March 25, 2022
An ISCT Stem Cell Engineering Committee Position Statement on Immune Reconstitution: the importance of predictable and modifiable milestones of immune reconstitution to transplant outcomesAlice Bertaina, Allistair Abraham, Carmem Bonfim, et al.
Cytotherapy|December 9, 2021
Curative therapy for hemoglobinopathies: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review comparing outcomes, accessibility and cost of ex vivo stem cell gene therapy versus allogeneic hematopoietic stem cell transplantationAlexis Leonard, Alice Bertaina, Carmem Bonfim, et al.
Blood Advances|July 19, 2023
Early cessation of calcineurin inhibitors is feasible post-haploidentical blood stem cell transplant: the ANZHIT 1 studyJohn Moore, Nada Hamad, David Gottlieb, et al.
Internal Medicine Journal|November 28, 2023
ANZTCT consensus position statement on ruxolitinib in steroid-refractory acute and chronic graft-versus-host diseaseNada Hamad, Ian Bilmon, Lynette Chee, et al.
Nature Medicine|June 6, 2024
Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trialYi-Bin Chen, Mohamad Mohty, Robert Zeiser, et al.
Cytotherapy|December 6, 2023
Engineering the best transplant outcome for high-risk acute myeloid leukemia: the donor, the graft and beyondSafia Belbachir, Allistair Abraham, Akshay Sharma, et al.
Pageof 6